NDATOPICALSYSTEM
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
LICART (diclofenac epolamine) by IBSA Institut Biochimique is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2018.
Drug data last refreshed 11h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LICART is a topical diclofenac epolamine patch approved in 2018 for localized pain and inflammation relief. It is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, thereby decreasing pain and inflammation at the site of application. The formulation includes heparin sodium and is designed for transdermal delivery without systemic anticoagulation effects.
$0.009BPart D
Peak8.4 years to LOEThe product is in peak commercial phase with $9M in Part D spending and modest claim volume, suggesting a niche but stable market position with lean commercial infrastructure.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury
Started Oct 2021
151 enrolled
Soft Tissue Injuries
Career Relevance
Worked on LICART at IBSA Institut Biochimique? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.